Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Cancer Res ; 29(23): 4797-4807, 2023 12 01.
Article in English | MEDLINE | ID: mdl-37782315

ABSTRACT

PURPOSE: To investigate whether circulating tumor DNA (ctDNA) assessment in patients with muscle-invasive bladder cancer predicts treatment response and provides early detection of metastatic disease. EXPERIMENTAL DESIGN: We present full follow-up results (median follow-up: 68 months) from a previously described cohort of 68 neoadjuvant chemotherapy (NAC)-treated patients who underwent longitudinal ctDNA testing (712 plasma samples). In addition, we performed ctDNA evaluation of 153 plasma samples collected before and after radical cystectomy (RC) in a separate cohort of 102 NAC-naïve patients (median follow-up: 72 months). Total RNA sequencing of tumors was performed to investigate biological characteristics of ctDNA shedding tumors. RESULTS: Assessment of ctDNA after RC identified metastatic relapse with a sensitivity of 94% and specificity of 98% using the expanded follow-up data for the NAC-treated patients. ctDNA dynamics during NAC was independently associated with patient outcomes when adjusted for pathologic downstaging (HR = 4.7; P = 0.029). For the NAC-naïve patients, ctDNA was a prognostic predictor before (HR = 3.4; P = 0.0005) and after RC (HR = 17.8; P = 0.0002). No statistically significant difference in recurrence-free survival for patients without detectable ctDNA at diagnosis was observed between the cohorts. Baseline ctDNA positivity was associated with the Basal/Squamous (Ba/Sq) subtype and enrichment of epithelial-to-mesenchymal transition and cell cycle-associated gene sets. CONCLUSIONS: ctDNA is prognostic in NAC-treated and NAC-naïve patients with more than 5 years follow-up and outperforms pathologic downstaging in predicting treatment efficacy. Patients without detectable ctDNA at diagnosis may benefit significantly less from NAC, but additional studies are needed.


Subject(s)
Carcinoma, Transitional Cell , Circulating Tumor DNA , Urinary Bladder Neoplasms , Humans , Carcinoma, Transitional Cell/drug therapy , Urinary Bladder Neoplasms/drug therapy , Urinary Bladder Neoplasms/genetics , Circulating Tumor DNA/genetics , Follow-Up Studies , Neoplasm Recurrence, Local/genetics , Neoadjuvant Therapy/methods
2.
Clin Cancer Res ; 29(8): 1582-1591, 2023 04 14.
Article in English | MEDLINE | ID: mdl-36780195

ABSTRACT

PURPOSE: To investigate the use of plasma and urine DNA mutation analysis for predicting neoadjuvant chemotherapy (NAC) response and oncological outcome in patients with muscle-invasive bladder cancer. EXPERIMENTAL DESIGN: Whole-exome sequencing of tumor and germline DNA was performed for 92 patients treated with NAC followed by radical cystectomy (RC). A custom NGS-panel capturing approximately 50 mutations per patient was designed and used to track mutated tumor DNA in plasma and urine. A total of 447 plasma samples, 281 urine supernatants, and 123 urine pellets collected before, during, and after treatment were analyzed. Patients were enrolled from 2013 to 2019, with a median follow-up time of 41.3 months after RC. RESULTS: We identified tumor DNA before NAC in 89% of urine supernatants, 85% of urine pellets, and 43% of plasma samples. Tumor DNA levels were higher in urine supernatants and urine pellets compared with plasma samples (P < 0.001). In plasma, detection of circulating tumor DNA (ctDNA) before NAC was associated with a lower NAC response rate (P < 0.001). Detection of tumor DNA after NAC was associated with lower response rates in plasma, urine supernatant, and urine pellet (P < 0.001, P = 0.03, P = 0.002). Tumor DNA dynamics during NAC was predictive of NAC response and outcome in urine supernatant and plasma (P = 0.006 and P = 0.002). A combined measure from plasma and urine supernatant tumor DNA dynamics stratified patients by outcome (P = 0.003). CONCLUSIONS: Analysis of tumor DNA in plasma and urine samples both separately and combined has a potential to predict treatment response and outcome.


Subject(s)
Neoadjuvant Therapy , Urinary Bladder Neoplasms , Humans , Neoadjuvant Therapy/adverse effects , DNA Mutational Analysis , Urinary Bladder Neoplasms/drug therapy , Urinary Bladder Neoplasms/genetics , Urinary Bladder Neoplasms/pathology , Cystectomy , Muscles/pathology , Chemotherapy, Adjuvant , Neoplasm Invasiveness/pathology , Retrospective Studies
3.
Hum Genet ; 130(4): 483-93, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21327791

ABSTRACT

In most people worldwide intestinal lactase expression declines in childhood. In many others, particularly in Europeans, lactase expression persists into adult life. The lactase persistence phenotype is in Europe associated with the -13910*T single nucleotide variant located 13,910 bp upstream the lactase gene in an enhancer region that affects lactase promoter activity. This variant falls in an Oct-1 binding site and shows greater Oct-1 binding than the ancestral variant and increases enhancer activity. Several other variants have been identified very close to the -13910 position, which are associated with lactase persistence in the Middle East and Africa. One of them, the -14010*C, is associated with lactase persistence in Africa. Here we show by deletion analysis that the -14010 position is located in a 144 bp region that reduces the enhancer activity. In transfections the -14010*C allele shows a stronger enhancer effect than the ancestral -4010*G allele. Binding sites for Oct-1 and HNF1α surrounding the -14010 position were identified by gel shift assays, which indicated that -14010*C has greater binding affinity to Oct-1 than -14010*G.


Subject(s)
Hepatocyte Nuclear Factor 1-alpha/genetics , Lactase/genetics , Lactose Intolerance/genetics , Octamer Transcription Factor-1/genetics , Polymorphism, Genetic/genetics , Promoter Regions, Genetic/genetics , Adult , Alleles , Binding Sites , Caco-2 Cells , DNA Footprinting , DNA Primers/chemistry , Electrophoretic Mobility Shift Assay , Enhancer Elements, Genetic/genetics , Hepatocyte Nuclear Factor 1-alpha/metabolism , Humans , Octamer Transcription Factor-1/metabolism , Transcription Factors/metabolism
4.
J Biol Chem ; 285(33): 25115-25, 2010 Aug 13.
Article in English | MEDLINE | ID: mdl-20551321

ABSTRACT

The CDX2 transcription factor is known to play a crucial role in inhibiting proliferation, promoting differentiation and the expression of intestinal specific genes in intestinal cells. The overall effect of CDX2 in intestinal cells has previously been investigated in conditional knock-out mice, revealing a critical role of CDX2 in the formation of the normal intestinal identity. The identification of direct targets of transcription factors is a key problem in the study of gene regulatory networks. The ChIP-seq technique combines chromatin immunoprecipitation (ChIP) with next generation sequencing resulting in a high throughput experimental method of identifying direct targets of specific transcription factors. The method was applied to CDX2, leading to the identification of the direct binding of CDX2 to several known and novel target genes in the intestinal cell. Examination of the transcript levels of selected genes verified the regulatory role of CDX2 binding. The results place CDX2 as a key node in a transcription factor network controlling the proliferation and differentiation of intestinal cells.


Subject(s)
Epithelial Cells/metabolism , Genome, Human/genetics , Homeodomain Proteins/metabolism , Intestines/cytology , Trans-Activators/metabolism , CDX2 Transcription Factor , Caco-2 Cells , Cell Differentiation/genetics , Cell Differentiation/physiology , Chromatin Immunoprecipitation , Computational Biology , Electrophoretic Mobility Shift Assay , Enhancer Elements, Genetic/genetics , Epithelial Cells/cytology , Hepatocyte Nuclear Factor 4/genetics , High Mobility Group Proteins/genetics , Homeodomain Proteins/genetics , Humans , Membrane Proteins/genetics , Metalloendopeptidases/genetics , Mutation , Promoter Regions, Genetic/genetics , Protein Binding/genetics , Protein Binding/physiology , Repressor Proteins/genetics , Reverse Transcriptase Polymerase Chain Reaction , Trans-Activators/genetics
5.
Am J Hum Genet ; 82(1): 57-72, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18179885

ABSTRACT

The T(-13910) variant located in the enhancer element of the lactase (LCT) gene correlates perfectly with lactase persistence (LP) in Eurasian populations whereas the variant is almost nonexistent among Sub-Saharan African populations, showing high prevalence of LP. Here, we report identification of two new mutations among Saudis, also known for the high prevalence of LP. We confirmed the absence of the European T(-13910) and established two new mutations found as a compound allele: T/G(-13915) within the -13910 enhancer region and a synonymous SNP in the exon 17 of the MCM6 gene T/C(-3712), -3712 bp from the LCT gene. The compound allele is driven to a high prevalence among Middle East population(s). Our functional analyses in vitro showed that both SNPs of the compound allele, located 10 kb apart, are required for the enhancer effect, most probably mediated through the binding of the hepatic nuclear factor 1 alpha (HNF1 alpha). High selection coefficient (s) approximately 0.04 for LP phenotype was found for both T(-13910) and the compound allele. The European T(-13910) and the earlier identified East African G(-13907) LP allele share the same ancestral background and most likely the same history, probably related to the same cattle domestication event. In contrast, the compound Arab allele shows a different, highly divergent ancestral haplotype, suggesting that these two major global LP alleles have arisen independently, the latter perhaps in response to camel milk consumption. These results support the convergent evolution of the LP in diverse populations, most probably reflecting different histories of adaptation to milk culture.


Subject(s)
Lactase/genetics , Milk/metabolism , Alleles , Animals , Camelus , Culture , Evolution, Molecular , Haplotypes , Humans , Lactase/metabolism , Lactose Tolerance Test , Middle East , Polymorphism, Single Nucleotide , Saudi Arabia
6.
Hum Mol Genet ; 14(24): 3945-53, 2005 Dec 15.
Article in English | MEDLINE | ID: mdl-16301215

ABSTRACT

Two phenotypes exist in the human population with regard to expression of lactase in adults. Lactase non-persistence (adult-type hypolactasia and lactose intolerance) is characterized by a decline in the expression of lactase-phlorizin hydrolase (LPH) after weaning. In contrast, lactase-persistent individuals have a high LPH throughout their lifespan. Lactase persistence and non-persistence are associated with a T/C polymorphism at position -13,910 upstream the lactase gene. A nuclear factor binds more strongly to the T-13,910 variant associated with lactase persistence than the C-13,910 variant associated with lactase non-persistence. Oct-1 and glyceraldehyde-3-phosphate dehydrogenase were co-purified by DNA affinity purification using the sequence of the T-13,910 variant. Supershift analyses show that Oct-1 binds directly to the T-13,910 variant, and we suggest that GAPDH is co-purified due to interactions with Oct-1. Expression of Oct-1 stimulates reporter gene expression from the T and the C-13,910 variant/LPH promoter constructs only when it is co-expressed with HNF1alpha. Binding sites for other intestinal transcription factors (GATA-6, HNF4alpha, Fox and Cdx-2) were identified in the region of the -13,910 T/C polymorphism. Three of these sites are required for the enhancer activity of the -13,910 region. The data suggest that the binding of Oct-1 to the T-13,910 variant directs increased lactase promoter activity and this might provide an explanation for the lactase persistence phenotype in the human population.


Subject(s)
Lactase/genetics , Octamer Transcription Factor-1/metabolism , Polymorphism, Genetic , Promoter Regions, Genetic/genetics , Binding Sites , Enhancer Elements, Genetic , Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+)/genetics , Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+)/isolation & purification , Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+)/metabolism , Hepatocyte Nuclear Factor 1-alpha/genetics , Hepatocyte Nuclear Factor 1-alpha/metabolism , Humans , Lactase/metabolism , Lactase-Phlorizin Hydrolase/genetics , Lactase-Phlorizin Hydrolase/metabolism , Lactose Intolerance/genetics , Octamer Transcription Factor-1/genetics , Transcription Factors/genetics , Transcription Factors/metabolism
7.
Radiat Prot Dosimetry ; 97(4): 375-81, 2001.
Article in English | MEDLINE | ID: mdl-11878423

ABSTRACT

Measurements in the real environment, i.e. with several different electromagnetic field (EMF) sources and scattering problems, require an accurate analysis of problems concerning narrowband measurements. The aim of the present work was the development of an automatic procedure for narrowband electric field measurements in open sites with multiple sources, in order to perform accurate and reproducible measurements. Results regarding measurements carried out in a suburban site are reported.


Subject(s)
Electromagnetic Fields , Environmental Exposure/analysis , Radiation Monitoring/methods , Automation , Environmental Pollution , Humans , Radio Waves
SELECTION OF CITATIONS
SEARCH DETAIL
...